CLINICAL TRIALS PROFILE FOR SAXENDA
✉ Email this page to a colleague
All Clinical Trials for saxenda
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02488057 ↗ | Improving Beta Cell Function in Mexican American Women With Prediabetes | Completed | Ohio State University | Phase 4 | 2016-05-01 | This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes. The Investigators have chosen to focus on MA women because MA women are at very high risk for progression to diabetes and have not traditionally been involved in weight management studies since they are thought to be difficult to recruit and retain in such programs. However, investigators have had particular success in working with young MA women using specifically developed ethnic and gender conscious programs. Because weight loss does not prevent all progression to diabetes, some participants will receive the diabetes medication, liraglutide, which has been shown to stabilize beta cell function. The study will also interrogate for polymorphisms of known T2DM genes to correlate with beta cell response to weight loss and liraglutide treatment. Additionally, this investigation targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population, testing novel gender and culturally focused intervention strategies and identifying genetic biomarkers of response to a pharmacologic intervention that targets the pancreatic ßcell. These results will help to a) understand mechanisms of disease, b) personalize treatment through identification of a high risk group that may be amenable to specific therapy, and c) ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and costly disease, in Mexican Americans. |
| NCT02647944 ↗ | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2015-12-18 | This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. |
| NCT02647944 ↗ | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Completed | Novo Nordisk A/S | Phase 2 | 2015-12-18 | This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. |
| NCT02647944 ↗ | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Completed | Mayo Clinic | Phase 2 | 2015-12-18 | This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for saxenda
Condition Name
Clinical Trial Locations for saxenda
Trials by Country
Clinical Trial Progress for saxenda
Clinical Trial Phase
Clinical Trial Sponsors for saxenda
Sponsor Name
